Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer

Cancer Research

Volumn 71, Issue 19, 2011, Pages 6250-6260

  Jiang, Ziyue Karen ^a   Sato, Makoto ^a   Wei, Liu H ^a   Kao, Chinghai ^b   Wu, Lily ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SODIUM FLUORIDE F 18;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE MARROW METASTASIS; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ENHANCER REGION; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE SPECIFIC ENHANCING SEQUENCE; REPORTER GENE; TIBIA; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; TWO STEP TRANSCRIPTIONAL AMPLIFICATION; VIRAL GENE DELIVERY SYSTEM;

ANDROGENS; ANIMALS; BONE MARROW; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; ORCHIECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGULATORY SEQUENCES, NUCLEIC ACID; TIBIA; TRANSCRIPTIONAL ACTIVATION;

EID: 80053345298     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1520     Document Type: Article

References (50)

1. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer. Curr Opin Oncol 2010;22:263-7.
2. Wang HQ, Yang B, Xu CL, Wang LH, Zhang YX, Xu B, et al. Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen-independent cells. Prostate 2010;70:508-17.
3. Figueiredo ML, Kao C, Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther 2007;15:1053-64. (Pubitemid 46813607)
4. De Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, et al. Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther 2010;21:795-805.
5. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009;15:3251-5.
6. Attard G, Reid AH, Olmos D, De Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69:4937-40.
7. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011;15:2108-17.
8. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
9. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgendeprivation therapy of prostate cancer fails. Oncogene 2010;29:3593-604.
10. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16. (Pubitemid 39665537)
11. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-30. (Pubitemid 23031827)
12. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen- deprivation therapy. Urology 1996;48:326-34. (Pubitemid 26279634)
13. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998;1443:113-27. (Pubitemid 29016015)
14. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
15. Zeng H, Wei Q, Huang R, Chen N, Dong Q, Yang Y, et al. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter. J Androl 2007;28:827-35. (Pubitemid 350058132)
16. Zhang P, Zeng H, Wei Q, Lu Y, Li X, Wang J, et al. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer. Int J Urol 2008;15:442-8. (Pubitemid 351623900)
17. Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 2002;6:415-21. (Pubitemid 36305345)
18. Sato M, Johnson M, Zhang L, Zhang B, Le K, Gambhir SS, et al. Optimization of adenoviral vectors to direct highly amplified prostatespecific expression for imaging and gene therapy. Mol Ther 2003;8:726-37. (Pubitemid 37527447)
19. Johnson M, Sato M, Burton J, Gambhir SS, Carey M, Wu L. Micro- PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol Imaging 2005;4:463-72. (Pubitemid 43143786)
20. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8. (Pubitemid 27145681)
21. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3:28-35. (Pubitemid 32509802)
22. Dzojic H, Cheng WS, Essand M. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model. Cancer Gene Ther 2007;14: 233-40.
23. Ray S, Paulmurugan R, Patel MR, Ahn BC, Wu L, Carey M, et al. Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther 2008;16: 1848-56.
24. Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, et al. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med 2008;49:1828-35.
25. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
26. Johnson M, Huyn S, Burton J, Sato M, Wu L. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 2006;17:1262-9. (Pubitemid 44975142)
27. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010;46:1223-31.
28. Lu Y, Chen Q, Corey E, Xie W, Fan J, Mizokami A, et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 2009;26:161-9.
29. Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, Lieberman JR. Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/ CT. J Nucl Med 2008;49:414-21. (Pubitemid 351355207)
30. Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2010;32: 168-76.
31. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, et al. C11-Acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011;36:192-8.
32. Bhang HE, Gabrielson KL, Laterra J, Fisher PB, Pomper MG. Tumorspecific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med 2011;17:123-9.
33. Sato M, Johnson M, Zhang L, Gambhir SS, Carey M, Wu L. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 2005;11: 3743-9. (Pubitemid 40685591)
34. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
35. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003;63:4552-60. (Pubitemid 36951029)
36. Burton JB, Johnson M, Sato M, Koh SB, Mulholland DJ, Stout D, et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 2008;14: 882-8.
37. Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002;8:891-7.
38. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, et al. Stromal factors involved in prostate carcinomametastasis to bone. Cancer 2003;97:739-47. (Pubitemid 36125809)
39. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 2008;14:1599-602. (Pubitemid 351469442)
40. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, et al. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol 2010;221:68-76.
41. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-fieldof- view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287-97. (Pubitemid 46780894)
42. Toegel S, Hoffmann O, Wadsak W, Ettlinger D, Mien LK, Wiesner K, et al. Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging 2006;33:491-4.
43. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis andstaging of clinically organ-confined prostate cancer. Urology 2001;57:108-11. (Pubitemid 32065829)
44. Oyama N, Akino H, Suzuki Y, Kanamaru H, Miwa Y, Tsuka H, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002;4:99-104. (Pubitemid 34272714)
45. Greig JA, Buckley SM, Waddington SN, Parker AL, Bhella D, Pink R, et al. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther 2009;17:1683-91.
46. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009;113:1909-18.
47. Liu H, Jin L, Koh SB, Atanasov I, Schein S, Wu L, et al. Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science 2010;329:1038-43.
48. Li HJ, Everts M, Yamamoto M, Curiel DT, Herschman HR. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Res 2009;69:554-64.
49. Yan M, Du J, Gu Z, Liang M, Hu Y, Zhang W, et al. A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol 2010;5:48-53.
50. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 2005;65:6882-90. (Pubitemid 41060727)